D. Boral Capital Lowers Immunic (NASDAQ:IMUX) Price Target to $4.00

Immunic (NASDAQ:IMUX) had its price target decreased by investment analysts at D. Boral Capital from $8.00 to $4.00 in a report released on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. D. Boral Capital’s price objective points to a potential upside of 359.72% from the company’s current price.

A number of other equities research analysts have also recently weighed in on IMUX. LADENBURG THALM/SH SH raised Immunic to a “strong-buy” rating in a report on Thursday, October 16th. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Immunic in a research note on Monday. Brookline Cap M raised Immunic to a “strong-buy” rating in a report on Tuesday, February 3rd. Chardan Capital upgraded shares of Immunic to a “strong-buy” rating in a research report on Wednesday, November 19th. Finally, Brookline Capital Acquisition upgraded shares of Immunic to a “strong-buy” rating in a research report on Tuesday, February 3rd. Four equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $6.60.

Immunic Stock Up 17.2%

Shares of IMUX stock opened at $0.87 on Friday. The company has a market capitalization of $104.66 million, a P/E ratio of -1.05 and a beta of 1.58. Immunic has a 12-month low of $0.51 and a 12-month high of $1.39. The firm has a 50-day moving average price of $0.63 and a 200 day moving average price of $0.76.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. As a group, research analysts expect that Immunic will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Immunic

Several institutional investors have recently modified their holdings of the business. Aberdeen Group plc lifted its holdings in Immunic by 678.1% in the second quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock valued at $5,750,000 after buying an additional 7,184,457 shares during the period. Millennium Management LLC raised its position in shares of Immunic by 414.5% during the 3rd quarter. Millennium Management LLC now owns 530,470 shares of the company’s stock valued at $468,000 after acquiring an additional 427,361 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of Immunic during the 3rd quarter valued at $239,000. Vanguard Group Inc. lifted its stake in shares of Immunic by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock valued at $3,832,000 after purchasing an additional 219,957 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in shares of Immunic in the 3rd quarter valued at $170,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.